 Shares of HOOKIPA Pharma NASDAQ:HOOK moved higher by 2.8 in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share increased 55.56 year over year to 0.28, which beat the estimate of 0.47.Revenue of 6,685,000 up by 65.02 year over year, which beat the estimate of 3,490,000.Outlook HOOKIPA Pharma hasnt issued any earnings guidance for the time being.View more earnings on HOOKHOOKIPA Pharma hasnt issued any revenue guidance for the time being.Recent Stock Performance Companys 52-week high was at 14.37Companys 52-week low was at 5.80Price action over last quarter: Up 16.72Company Overview HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the bodys immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.See more from Benzinga Earnings Scheduled For August 13, 2020C 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 